Table 3. Summary of Sensitivities of the commercial tests across the years of infection and at different time points.

	SENSITIVITY (95% Confidence Interval)
	PANBIO RLF			LABNOVATION RLF			PLATELIA ELISA
TIMEPOINTS	Y2020 N = 130	Y2021 N = 88	Y2022 N = 17	Y2020 N = 130	Y2021 N = 88	Y2022 N = 17	Y2020 N = 130	Y2021 N = 88	Y2022 N = 17
Day of diagnostic (DoD)	N = 127 46% (37.3%–54.3%)	N = 83 23% (15.1%–33%)	N = 17 70% (47%–87%)	N = 127 41% (33%–50%)	N = 83 19% (12.2%–29%)	N = 17 67% (41.3%–83%)	N = 123 47% (38%–55.1%)	N = 80 39% (29%–49.3%)	N = 17 71% (47%–87%)
14 days Post-DoD	N = 62 87% (77%–93.3%)	N = 45 76% (61.3%–86%)	N = 17 88% (66%–98%)	N = 62 65% (52.1%–54.3%)	N = 45 69% (54.3%–81%)	N = 17 82% (59%–94%)	N = 60 89% (78.4%–94.4%)	N = 44 84% (71.2%–92.2%)	N = 16 94% (73%–100%)
44 days Post-DoD	N = 45 89% (76%–95.1%)	N = 39 77% (62%–87.4%)	-	N = 45 89% (76%–95.1%)	N = 39 62% (50%–75.1%)	–	N = 42 93% (82%–98%)	N = 39 72% (56.2%–84%)	–
74 days Post-DoD	N = 31 81% (64.2%–91.1%)	N = 31 60% (42.3%–75.4%)	–	N = 31 81% (64.2%–91.1%)	N = 31 67% (49%–81%)	–	N = 30 90% (75.1%–97%)	N = 30 73% (56%–86%)	–
104 days Post-DoD	N = 18 83% (61%–94.2%)	N = 28 54% (365–70.4%)	–	N = 18 50% (29%–71%)	N = 28 46% (30%–64.2%)	–	N = 18 89% (67.2%–985)	N = 25 71% (53%–85%)	–
134 days Post-DoD	N = 17 77% (53%–90.4%)	N = 26 23% (11%-42%)	–	N = 17 52% (31%–74%)	N = 26 35% (19.4%–54%)	–	N = 17 88% (66%–98%)	N = 26 69% (50%–84%)	–
164 days Post-DoD	N = 14 64% (39%–84%)	N = 24 25% (12%–45%)	–	N = 14 71% (45.4%–88.3%)	N = 24 29% (15%–49.1%)	–	N = 14 86% (60.1–98%)	N = 24 88% (69%–96%)	–
194 days Post-DoD	N = 9 56% (27%–81.1%)	N = 17 29% (13.2%–53.1%)	–	N = 9 44% (19%–733.3%)	N = 17 29% (13.2%–53.1%)	–	N = 9 89% (57%–99.4%)	N = 17 77% (53%–90.4%)	–